Chemotherapy of human breast-carcinoma xenografts. by Bailey, M. J. et al.
Br. J. Cancer (1980) 42, 530
CHEMOTHERAPY OF HUMAN BREAST-CARCINOMA XENOGRAFTS
M. J. BAILEY*t, J.-C. GAZETtt, I. E. SMITH*t AND G. G. STEEL*
From the *Institute ofCancer Research and tRoyal Marsden Hospital, Sutton, Surrey, and
tSt George's Hospital, Tooting, London
Received 18 April 1980 Accepted 2 June 1980
Summary.-Five lines of human breast-carcinoma xenografts have been tested for
sensitivity to cyclophosphamide, methotrexate, 5-fluorouracil, adriamycin, vincris-
tine and melphalan, alone and in combination, using tumour growth delay as an end-
point. The xenograft lines were established and passaged in miceimmune-suppressed
by thymectomy and whole-body irradiation. There was a considerable range ofsensi-
tivity of the different lines to the agents studied, and within this variation there was
evidence that the most effective single agent or combination differed for each tumour.
Combination chemotherapy was more effective than single agents in 3 of the lines,
but melphalan was more effective than either combination in the other 2. It is sugges-
ted that a panel of human breast tumours grown in immune-suppressed mice may
prove useful in testing new cytotoxic agents for activity against breast cancer before
their use in clinical trials, and that more effective combinations of existing drugs
might be designed with the aid of this system.
ALTHOUGH COMBINATION CHEMOTHER-
APY can achieve tumour regression in most
patients with advanced breast cancer,
responses are usually of short duration,
and such treatment is rarely curative
(Carter, 1976). Even the use of adjuvant
chemotherapy early in the clinical course
of the disease in poor-risk patients seems
likely to improve survival in only a small
percentage of patients (Bonnadonna,
1980). There is an obvious need therefore
to find better drugs or better combinations
of existing drugs in the treatment of this
disease, and an important question is how
such agents should be identified.
In this paper, we describe the response
to single agents and cytotoxic drug com-
binations of 5 human breast-carcinoma
xenografts grown andpassagedin immune-
suppressed mice, and we suggest that this
system may be a useful model for predict-
ing clinical chemotherapy response.
MATERIALS AND METHODS
Mice.-Female CBA/lac mice bred at the
Institute of Cancer Research breeding station
were used. They were thymectomized at 4
weeks of age, and 2-4 weeks later were
exposed to 9 Gy whole-body irradiation, pre-
ceded 48 h earlier by 200 mg/kg cytosine
arabinoside (AraC) i.p. Tumour implantation
was performed on the day after irradiation.
Tumours.-The 5 xenograft lines used were
established and maintained in immune-
suppressed mice. The technique of immune
suppression of the mice and details of the
initiation of the xenograft lines are fully
described elsewhere (Steel et al., 1978; Bailey
et al., 1980). The histology of the donor pa-
tients was as follows:
HX 99 Infiltrativeintraduct carcinoma,axil-
lary-node-positive, Bloom and Richardson
(B and R) Grade III.
HX 100-Infiltrating ductal, node-positive,
B and R Grade II.
HX 104-Infiltrating intraduct, node-posi-
tive, B and R Grade III.
HX 105-Infiltrating ductal, marked comedo
pattern, node-negative, B and R Grade II.
HX 106-Infiltrating ductal carcinoma with
comedo pattern, B and R Grade III, node-
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The human nature ofthese tumours has been
confirmed by chromosome analysis, histo-
pathology and immunocytochemical tech-
niques (Bailey in preparation).
Tumour measurement.-Tumours for drug
experiments were implanted s.c. on both
sides of the mouse at the dorsal aspect of the
costal margin. Throughout the experiment
tumours were measured twice weekly, in two
dimensions at right angles to each other using
Vernier calipers. Volume was calculated from
the formula V= 7rT6 (mean diameter)3. For
chemotherapy studies, tumours of 20-50
mm3 were used, and 10 mice (20 tumours)
were included in each group.
Drug therapy.-Single-agent chemotherapy
was given as a single i.p. injection. The dose
lethal to 10% ofmice (LD1o) was obtained for
immune-suppressed female CBA/lac mice.
For dose-response studies, 3 dose levels were
used, LD10, 2/3 LD10 and 1/3 LD10. In
combination chemotherapy experiments the
two combinations were designed to imitate
those in widest clinical use at the Royal
Marsden Hospital, viz.
Total
/cycle
mg/iM2
CMF:
Cyclophosphamide (C) 100 mg/M2
Days 1-14 1400
Methotrexate (M) 30 mg/Mi2 Days 1
and 8 60
5-Fluorouracil (F) 600 mg/M2 Days
I and 8 1200
AV:
Adriamycin (A) 40 mg/Mi2 Days
I and 8 80
Vincristine (V) 1-4 mg/M2 Days
I and8 2-8
The doses given to mice maintained the drugs
in the above ratio of the total dose per cycle,
given as a single i.p. injection. The LD10 of
each combination and agent was experi-
mentally derived from toxicity studies in the
strain of mice used. LD10 values for immuno-
suppressed female CBA/lac mice were: C
280 mg/kg, M 100 mg/kg, F 180 mg/kg, A
12 mg/kg, V 2-1 mg/kg, melphalan (Me)
14 mg/kg, CMF 180/10/150 mg/kg, AV 10/0 3
mg/kg. Drugs were freshly made up for each
experiment.
Presentation of results.-Growth curves
show the mean relative tumour volume
(Vt/Vo) of control and treated tumours
plotted against time in days after treatment:
Vt volume oftumour at time 0
Vo = volume of tumour at time of treat-
ment
From these growth curves, the specific
growth delay (SGD) for each drug dose in
each tumour has been calculated, and the
results presented as dose-response curves:
SGD =
TD treated tumours -
TD time of control tumours
TD of control tumours
TD=time taken for each tumour to double
in volume from the treatment size. Calculated
in this way, the SGD values represent the
number of tumour volume-doubling times
saved by the chemotherapy. The dose-
response curves allow comparison ofthe effect
of equitoxic doses of drugs against each
tumour line, and of the effect of each drug
against the different tumour lines, allowing
for differences in the tumour volume-doubling
time.
RESULTS
All 5 xenograft lines have been tested
against the 6 single agents and the 2
combinations mentioned above. The
growth delay achieved by each agent and
combination given at the LD10 dose for
each tumour line is shown in Table I. One
or other of the 2 combinations, CMF
or AV, was the most effective therapy in
3 of the lines, and second most effective
in 4. The mean SGD achieved for all the
tumour lines by these 2 combinations
was almost identical (CMF= 2-8, AV=
2.7). Of the single agents, melphalan (Me)
proved the most effective overall, and in
two lines (HX104 and 106) produced a
greater SGD than either of the combina-
tions. The mean growth delay seen with
melphalan was 2-2, slightly longer than
that attained by adriamycin (1.9) or
cyclophosphamide and 5-fluorouracil, both
with a mean SGD of 1-7. The performance
of vincristine and methotrexate was poor
in comparison with the other agents. As
MTX is a cell-cycle-specific agent, it is
likely that a single dose was not the most
effective schedule, but an experiment in
which 3 divided doses of MTX were given
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TABLE I.-Volume-doubling times saved for each tumour by each drug or combination at
LD1o. Best treatmentfor each xenograft in bold type
HX No.
Drug , 99 100 104 105 106 Mean
CMF 4*9 341 1-5 2-8 1*5 2*8
AV 6-5 3-8 0-8 1-5 1.0 2*7
Melphalan 2-7 241 2-2 1.9 2-2 2-2
Adriamycin 4-1 3-1 0 5 1-2 0-6 1.9
Cyclophosphamide 3-2 1-7 1.1 1-5 0 9 1-7
5-Fluorouracil 2-2 2-5 0-8 2-4 0 5 1V7
Vincristine 2-5 1-2 0-7 0-5 0-4 1.1
Methotrexate 1-0 0-5 0-6 0-5 0-2 0-6
Mean 3-4 3-0 1.0 1-5 0-9
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general pattern of tumour response was
initial regression, followed by a phase of
slow growth, and ultimately regrowth at a
rate equal to that of the control tumours.
The dose-response curves for all the
agents studied were linear, within the
limits of experimental error, there being
no evidence for either a shoulder or a
plateau effect with any drug (Figs. 2-6).
When the contribution of single agents to
the combinations is studied, it can be seen
that although the SGD ofthe combination
at LD10 is greater than that of any ofthe
single agents, the result is not greater than
additive. For example, in HX105 (Fig. 5)
the contribution of the single agents is
shown in Table II. The total SGD achieved
TABLE II.-Contribution of single agents
to CMF effect (on HX 105)
Drug
Cyclophosphamide
Methotrexate
5-Fluorouracil
FIG. 1.-Growth curves for the 5 xenografted
lines treated i.p. with LD1o doses of CMF,
AV and Me on Day 0.
in a 24h period in 2 lines (HX 99 and
106) showed a SGD of 1-2 and 0-3, an
insignificant improvement on the SGD in a
single-dose regime of 1-0 and 0-2 respec-
tively.
Growth curves for each tumour line
against CMF, AV and Me are shown in
Fig. 1. From these it can be seen that the
SGD at LD1o
1-5
0-5
2-4
Total
CMF
by the constituent drugs of a combination
at the dose ofthose drugs used in the LDjo
dose of the combination summates to the
SGD of that combination at its LD10.
This was true for each ofthe other tumour
lines tested.
No complete regressions or tumour
''cures") were achieved by any agent or
combination of agents, in contrast to
xenografts of oat-cell carcinoma of the
bronchus (Shorthouse et al., 1980).
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FIG. 2.-Dose-response curve for HX99 treated with cyclophosphamide(C) methotrexate (Mx)
5-fluorouracil (5-Fu) individually and in combination (CMF); adriamycin (A) and vincristine
(V) alone and in combination (AV) and melphalan (Me). The * corresponds to the dose of each
single agent used in the LD10 dose of the combination.
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FIG. 3.-Dose-response curve for HXl00 treated as HX99 in Fig. 2.
DISCUSSION
Human breast tumour xenografts have
been described previously in nude mice
(Shimosato, 1976; Giovanella, 1976), but
the xenografts used in this study are the
first reported human breast-cancer xeno-
grafts to be established and maintained in
immune-suppressed animals (Bailey et al.,
1980a). The immune-suppressed mouse is
about one-fifth the cost of a nude mouse,
an important point when considering
experimental chemotherapy studies in
AV
IA
1-0
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FIG. 4.-Dose-response curve for HX104 treated as HX99 in Fig. 2.
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FIG. 5.-Dose-response curve for HX105 treated as HX99 in Fig. 2.
which several hundred mice may be
needed. It is also less vulnerable to the
various infections that have affected some
nude mouse colonies. This study has shown
that it is now possible to obtain reproduc-
ible chemosensitivity data for human
breast-tumour xenografts using the tech-
nique of tumour growth delay, and has
allowed us to make several important
observations.
First, for all 5 xenografts, combination
chemotherapy was more effective than
each of the single agents in the combina-
tion given alone at equitoxic dose. This
does not indicate a synergistic or super-
additive effect, because the data show
that the growth delay achieved by each
agent at the dose used in the combination
summates to the growth delay of the
combination itself, within the limit of
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FIG. 6. Dose-response curve for HX106 treated as HX99 in Fig. 2.
experimental error. The greater cyto-
toxicity effect ofthe combination has been
achieved because the toxicity to normal
tissues ofeach agent was less thanadditive.
For example, the LD10 dose of CMF con-
tains 80% of the LD1o dose of C, 90%o of
F and 10%/ of M. This experimental
observation reflects and reinforces a clini-
cal principal already well established in
combination chemotherapy for breast car-
cinoma (Carter, 1976).
Second, there was considerable variation
between the innate chemosensitivities of
the tumours. For example, xenograft
HX99 was more than 6 times as sensitive
to the AV combination as xenograft
HX104, and more than 3 times as sensitive
to the combination CMF, as measured by
number of volume doublings saved. This
has also been shown for other human
tumour xenografts, including melanoma
(Selby et al., 1980) and small-cell lung
carcinoma (Shorthouse et al., 1980). Like-
wise, this experimental finding reflects
clinical experience in breast-cancer chemo-
therapy, in which a small percentage of
patients achieve a complete response, a
larger percentage a partial response, and
30-40%o no response (Carter, 1976). What
is of great interest in this study was the
further finding that the most effective
drug combination or single drug varied
for each tumour. In two xenografts, AV
was the most effective combination, in one
xenograft CMF was the most effective,
and in two xenografts the single agent
melphalan was more effective than either
of the combinations. This variation
between tumours is in contrast to a similar
study recently carried out for human
small-cell lung-carcinoma xenografts
(Shorthouse et al., 1980). The finding raises
obvious doubts about the clinical practice
ofusing the same type of chemotherapy to
treat all patients with advanced breast
cancer, and suggests that patients who fail
to respond to one form of chemotherapy
may nevertheless achieve a response on an
alternative non-cross-reacting regimen.
Once more, this experimental observation
supports clinical studies which have sug-
gested that patients who fail to respond
or who relapse on one form of chemo-
therapy have around a 3000 chance of
responding to an alternative regimen
(Brambilla et al., 1976).
Although the experimental observations
so far discussed show a good correlation
with clinical experience, there is never-
theless one area in which an apparent
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contradiction appears: melphalan was the
most active single agent in all but one
xenograft, and indeed was more effective
than non-melphalan-containing combina-
tions in two. In contrast clinical experi-
ence suggests that this drug is no more
effective than other single agents, and is
significantly less effective than combina-
tion chemotherapy (Carter, 1976). It is
possible that pharmacological differences
between murine and human handling of
melphalan may explain this contrast
and it is equally possible that the xeno-
grafts studied are atypical in their chemo-
sensitivity. Both of these possibilities
represent valid theoretical objections to
the clinical application of xenograft data.
On the other hand, it may be that the
melphalan data have clinical relevance,
which merits further clinical examination
of this drug: in most studies melphalan
has been used in low doses over several
days in the treatment of breast cancer,
whereas the linear dose response demon-
strated here suggests that intermittent
high-dose therapy with this agent may be
more effective and worthy of clinical trial.
It is important to note the limitations
of this system to applied clinical research.
First, pharmacological and pharmaco-
kinetic differences may exist between
mouse and man for at least some of the
drugs used, and studies are required to
investigate this further. Second, the timing
of drug schedules used in the clinic is
difficult to mimic in the mouse. Third, the
take rate for breast-tumour xenografts is
at present low (Bailey et al., 1980) and
the tumours grown may be atypical in
their chemosensitivity. Finally, it appears
most unlikely that this system can be used
to determine the most effective chemo-
therapy for individual patients, because
of the low take rate, cost and length of
time required to establish each xenograft.
On the other hand, clinical trials are
time-consuming and difficult to control,
and we are encouraged at the correlation
already found between these experimental
studies and clinical experience in treating
breast carcinoma. We feel that the human
breast-cancer xenograft system may well
represent a valid and useful model for
planning new approaches to clinical
chemotherapy. Two areas in particular
may prove of value. First, the system
allows the contribution of each single
agent to a drug combination to be evalu-
ated. On this basis it may prove possible
to design new and more effective combina-
tions of existing drugs more quickly and
more efficiently than can be currently
achieved by clinical trials. Second, new
drugswithpotential activity can bereadily
tested in this series of xenografts before
clinical studies. The chemosensitivity of
such agents can be compared to the data
already obtained for conventional agents,
and it may well prove possible with this
system to decide with some confidence
which new agents should have the highest
priority for immediate clinical studies.
The work above was supported by the Breast
Cancer Trust Fund.
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